– USA, MD – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on the treatment of immune dysregulation, announced the appointment of Dr. Rita Jain (M.D.) to its Board of Directors.
About Dr. Rita Jain
Dr. Rita Jain is a Rheumatologist who brings over two decades of leadership experience in biopharmaceutical development, clinical strategy, and regulatory affairs across multiple therapeutic areas, including immunology, inflammation, nephrology, and rare diseases. She most recently served as EVP and CMO at ChemoCentryx, where she advanced development and supported commercialization of Tavneos (avacopan), a first-in-class treatment for ANCA-associated vasculitis, and supported the company’s acquisition by Amgen in 2022. Before that, she was SVP and CMO at Akebia Therapeutics. Additionally, Dr. Jain held key leadership positions at AbbVie, Pfizer, and Immunovant, overseeing global development programs, regulatory interactions, and clinical operations for multiple therapeutic candidates. She also serves on the boards of Celldex Therapeutics and AnaptysBio.
Dr. Rita Jain received her M.D. from the State University of New York at Stony Brook School of Medicine and completed her residency in internal medicine at Staten Island University Hospital, followed by a fellowship in rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
For more: https://www.avalotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.